Can-Fite BioPharma (NYSEAMERICAN:CANF) has been assigned a $7.00 price objective by stock analysts at Maxim Group in a research report issued on Monday. The firm currently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 430.30% from the stock’s previous close.
CANF has been the topic of several other research reports. ValuEngine cut shares of Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 7th. HC Wainwright set a $6.00 price target on shares of Can-Fite BioPharma and gave the company a “buy” rating in a research report on Tuesday, October 31st.
Shares of Can-Fite BioPharma (CANF) traded up $0.04 on Monday, reaching $1.32. 81,500 shares of the company’s stock traded hands, compared to its average volume of 56,951. Can-Fite BioPharma has a 52 week low of $1.24 and a 52 week high of $2.67.
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.